

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64200 A2

(51) International Patent Classification⁷: **A61K 31/00**,
31/505, 31/506, A61P 13/12

(21) International Application Number: PCT/EP01/02340

(22) International Filing Date: 1 March 2001 (01.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00810181.8 3 March 2000 (03.03.2000) EP

(71) Applicants (for all designated States except US): **NOVARTIS AG** [CH/CH]; Schwarzwaldallee 215, CH-4058 Basle (CH). **THE UNIVERSITY OF MELBOURNE** [AU/AU]; Parkville, VIC 3052 (AU). **SOUTHERN HEALTH** [AU/AU]; Monash Medical Center, 246 Clayton Road, Clayton, VIC 3168 (AU).

(71) Applicants and

(72) Inventors: **ATKINS, Robert, Charles** [AU/AU]; 7 Wentworth Avenue, Canterbury, VIC 3126 (AU). **CHADBAN, Steven, James** [AU/AU]; 73 Ardoyne Street, Blackrock, VIC 3193 (AU). **COOPER, Mark, Emmanuel** [AU/AU]; 50 Molesworth Street, Kew, VIC 3101 (AU). **GILBERT, Richard, Ernest** [AU/AU]; 16 Mary Street, West St. Kilda, VIC 3182 (AU). **HILL, Prudence, Ann** [AU/AU]; 7 Wentworth Avenue, Canterbury, VIC 3126

(AU). **KELLY, Darren, James** [AU/AU]; 1 Commerford Place, Chirnside Village, VIC 3116 (AU). **NIKOLIC-PATERSON, David, John** [GB/AU]; 170 Mt. Grantview Road, Pearcedale, VIC 3912 (AU).

(74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY

(57) Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R₁ is pyridyl bonded at a carbon atom, R₂, R₃, R₅, R₆ and R₈ are each hydrogen, R₄ is lower alkyl, R₇ a radical of formula (II): -N(R₉)-C(=X)-(Y)_n-R₁₀, wherein R₉ is hydrogen, X is oxo, n is 0 and R₁₀ is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.




WO 01/64200 A2

Use of PDGF Receptor Tyrosine Kinase Inhibitors for the Treatment of Diabetic Nephropathy

The present invention relates to a new use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula I in which the symbols and substituents have the meaning as given hereinafter in free form or in pharmaceutically acceptable salt form, said compound group being referred to hereinafter collectively as COMPOUNDS OF THE INVENTION, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy, and to a method of treatment of warm-blooded animals, including humans, in which a therapeutically effective dose of a COMPOUND OF THE INVENTION is administered to a warm-blooded animal suffering from diabetic nephropathy.

The present invention relates the use of PDGF receptor tyrosine kinase inhibitors for the manufacture of a medicament for treating diabetic nephropathy.

The present invention relates in particular to a new use of N-phenyl-2-pyrimidine-amine derivatives of formula I,




wherein

R₁ is 4-pyrazinyl; 1-methyl-1H-pyrrolyl; amino- or amino-lower alkyl-substituted phenyl, wherein the amino group in each case is free, alkylated or acylated; 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom; or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen;

R₂ and R₃ are each independently of the other hydrogen or lower alkyl;

one or two of the radicals R_4 , R_5 , R_6 , R_7 and R_8 are each nitro, fluoro-substituted lower alkoxy or a radical of formula II



wherein

R_9 is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R_{10} is an aliphatic radical having at least 5 carbon atoms, or an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical,

and the remaining radicals R_4 , R_5 , R_6 , R_7 and R_8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino or free or esterified carboxy,

or of a salt of such a compound having at least one salt-forming group,
for the manufacture of a medicament for treating diabetic nephropathy.

1-Methyl-1H-pyrrolyl is preferably 1-methyl-1H-pyrrol-2-yl or 1-methyl-1H-pyrrol-3-yl.

Amino- or amino-lower alkyl-substituted phenyl R_1 , wherein the amino group in each case is free, alkylated or acylated is phenyl substituted in any desired position (ortho, meta or para) wherein an alkylated amino group is preferably mono- or di-lower alkylamino, for example dimethylamino, and the lower alkyl moiety of amino-lower alkyl is preferably linear C_1 - C_3 alkyl, such as especially methyl or ethyl.

1H-Indolyl bonded at a carbon atom of the five-membered ring is 1H-indol-2-yl or 1H-indol-3-yl.

Unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom is lower alkyl-substituted or preferably unsubstituted 2-, 4- or preferably 3-pyridyl, for example 3-

pyridyl, 2-methyl-3-pyridyl or 4-methyl-3-pyridyl. Pyridyl substituted at the nitrogen atom by oxygen is a radical derived from pyridine N-oxide, i.e. N-oxido-pyridyl.

Fluoro-substituted lower alkoxy is lower alkoxy carrying at least one, but preferably several, fluoro substituents, especially trifluoromethoxy or 1,1,2,2-tetrafluoro-ethoxy.

When X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydrox-imino, the group C=X is, in the above order, a radical C=O, C=S, C=N-H, C=N-lower alkyl, C=N-OH or C=N-O-lower alkyl, respectively. X is preferably oxo.

n is preferably 0, i.e. the group Y is not present.

Y, if present, is preferably the group NH.

The term "lower" within the scope of this text denotes radicals having up to and including 7, preferably up to and including 4 carbon atoms.

Lower alkyl R₁, R₂, R₃ and R₉ is preferably methyl or ethyl.

An aliphatic radical R₁₀ having at least 5 carbon atoms preferably has not more than 22 carbon atoms, generally not more than 10 carbon atoms, and is such a substituted or preferably unsubstituted aliphatic hydrocarbon radical, that is to say such a substituted or preferably unsubstituted alkynyl, alkenyl or preferably alkyl radical, such as C₅-C₇alkyl, for example n-pentyl. An aromatic radical R₁₀ has up to 20 carbon atoms and is unsubstituted or substituted, for example in each case unsubstituted or substituted naphthyl, such as especially 2-naphthyl, or preferably phenyl, the substituents preferably being selected from cyano, unsubstituted or hydroxy-, amino- or 4-methyl-piperazinyl-substituted lower alkyl, such as especially methyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino and free or esterified carboxy. In an aromatic-aliphatic radical R₁₀ the aromatic moiety is as defined above and the aliphatic moiety is preferably lower alkyl, such as especially C₁-C₂alkyl, which is substituted or preferably unsubstituted, for example benzyl. A cycloaliphatic radical R₁₀ has especially up to 30, more especially up to 20, and most especially up to 10 carbon atoms, is mono- or poly-cyclic and is substituted or preferably unsubstituted, for example such a cycloalkyl radical, especially such a 5- or 6-membered

cycloalkyl radical, such as preferably cyclohexyl. In a cycloaliphatic-aliphatic radical R_{10} the cycloaliphatic moiety is as defined above and the aliphatic moiety is preferably lower alkyl, such as especially C_1 - C_2 alkyl, which is substituted or preferably unsubstituted. A heterocyclic radical R_{10} contains especially up to 20 carbon atoms and is preferably a saturated or unsaturated monocyclic radical having 5 or 6 ring members and 1-3 hetero atoms which are preferably selected from nitrogen, oxygen and sulfur, especially, for example, thienyl or 2-, 3- or 4-pyridyl, or a bi- or tri-cyclic radical wherein, for example, one or two benzene radicals are annellated (fused) to the mentioned monocyclic radical. In a heterocyclic-aliphatic radical R_{10} the heterocyclic moiety is as defined above and the aliphatic moiety is preferably lower alkyl, such as especially C_1 - C_2 alkyl, which is substituted or preferably unsubstituted.

Etherified hydroxy is preferably lower alkoxy. Esterified hydroxy is preferably hydroxy esterified by an organic carboxylic acid, such as a lower alkanolic acid, or a mineral acid, such as a hydrohalic acid, for example lower alkanoyloxy or especially halogen, such as iodine, bromine or especially fluorine or chlorine.

Alkylated amino is, for example, lower alkylamino, such as methylamino, or di-lower alkylamino, such as dimethylamino. Acylated amino is, for example, lower alkanoylamino or benzoylamino.

Esterified carboxy is, for example, lower alkoxycarbonyl, such as methoxycarbonyl.

A substituted phenyl radical may carry up to 5 substituents, such as fluorine, but especially in the case of relatively large substituents is generally substituted by only from 1 to 3 substituents. Examples of substituted phenyl that may be given special mention are 4-chloro-phenyl, pentafluoro-phenyl, 2-carboxy-phenyl, 2-methoxy-phenyl, 4-fluoro-phenyl, 4-cyano-phenyl and 4-methyl-phenyl.

Salt-forming groups in a compound of formula I are groups or radicals having basic or acidic properties. Compounds having at least one basic group or at least one basic radical, for example a free amino group, a pyrazinyl radical or a pyridyl radical, may form acid addition salts, for example with inorganic acids, such as hydrochloric acid, sulfuric acid or a phosphoric acid, or with suitable organic carboxylic or sulfonic acids, for example aliphatic mono- or di-carboxylic acids, such as trifluoroacetic acid, acetic acid, propionic acid, glycolic

acid, succinic acid, maleic acid, fumaric acid, hydroxymaleic acid, malic acid, tartaric acid, citric acid or oxalic acid, or amino acids such as arginine or lysine, aromatic carboxylic acids, such as benzoic acid, 2-phenoxy-benzoic acid, 2-acetoxy-benzoic acid, salicylic acid, 4-aminosalicylic acid, aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid, heteroaromatic carboxylic acids, such as nicotinic acid or isonicotinic acid, aliphatic sulfonic acids, such as methane-, ethane- or 2-hydroxyethane-sulfonic acid, or aromatic sulfonic acids, for example benzene-, p-toluene- or naphthalene-2-sulfonic acid. When several basic groups are present mono- or poly-acid addition salts may be formed.

Compounds of formula I having acidic groups, for example a free carboxy group in the radical R_{10} , may form metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri-(2-hydroxyethyl)-amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'-dimethyl-piperazine.

Compounds of formula I having both acidic and basic groups can form internal salts.

For the purposes of isolation or purification, as well as in the case of compounds that are used further as intermediates, it is also possible to use pharmaceutically unacceptable salts. Only pharmaceutically acceptable, non-toxic salts are used for therapeutic purposes, however, and those salts are therefore preferred.

Further suitable PDGF receptor tyrosine kinase inhibitors are disclosed in WO 98/35958, especially the compound of Example 62, and US 5,093,330 in each case in particular in the compound claims and the final products of the working examples, the subject-matter of which are hereby incorporated into the present application by reference to these publications.

Diabetic nephropathy is characterized by a persistent albuminuria (> 300 mg/ 24 h or $200 \mu\text{g}/\text{min}$), which disease can be diagnosed clinically if the following additional criteria are fulfilled: presence of diabetic retinopathy and no clinical or laboratory evidence of kidney or urinary tract disease other than diabetic glomerulosclerosis. Diabetic nephropathy is the commonest cause of endstage renal failure in the Western World.

Short description of the drawings

Figure 1: Glomerular cellularity as assessed by the number of nuclei (mean \pm SD) per glomerular cross section (gcs) in 50 hilar glomeruli per animal. Glomerular hypercellularity is significantly attenuated by CGP 57148B. * $p < 0.05$.

Figure 2: Mesangial cell proliferation as assessed by the number of BrdU+/ED1- cells (mean \pm SEM) per glomerular cross section (gcs) in 50 hilar glomeruli per animal. Mesangial cell proliferation is significantly attenuated by CGP 57148B. * $p < 0.001$.

Figure 3: Activated mesangial cells as assessed by the number of α -smooth muscle actin immunostained cells (mean \pm SEM) per glomerular cross section (gcs) in 50 hilar glomeruli per animal from untreated and CGP 57148B-treated rats. * $p < 0.05$.

Figure 4: Quantitation of type IV collagen as assessed by the fractional area (mean \pm SD) of the glomerulus that is immunostained. * $p < 0.05$ versus untreated rats.

It can be shown by established test models and especially those test models described herein that the COMPOUNDS OF THE INVENTION or in each case a pharmaceutically acceptable salt thereof, results in a more effective prevention or preferably treatment especially of diabetic nephropathy, but also of glomerulonephritis, chronic pyelonephritis or IgA nephropathy. The person skilled in the pertinent art is fully enabled to select a relevant test model to prove the hereinbefore and hereinafter indicated therapeutic indications and beneficial effects. The pharmacological activity may, for example, be demonstrated in a clinical study or in the test procedure as essentially described hereinafter.

Test Example 1: Antiproteinuric action in rats with subtotally (5/6) nephrectomy [focal glomerulosclerosis model; T.W. Meyer and H.G. Renake, Am. J. Physiol. 254, F856 (1988)].

Five-week-old male rats are anesthetized by intraperitoneal injection of pentobarbital sodium and 2/3 of the right kidney is removed. One week later, the entire left kidney is removed under similar anesthesia. After two-week breeding, 24-hour urine is collected and the total protein content and albumin content in the urine is determined by the use of A/G-B test (Wako Pure Chemical Co., Ltd.). On the basis of urinary protein and blood pressure the rats are divided into two groups (vehicle-treated rats and rats treated with 1 mg/kg/day, p.o. of a COMPOUND OF THE INVENTION). Rats undergoing nephrectomy of the left kidney alone are also used as sham operated rats. The COMPOUND OF THE INVENTION is suspended in gum-arabic and the suspension is orally administered once a day for eight week. At the 2nd, 4th, 6th and 8th week of the treatment, 24-hour urine is collected for the determination of urinary total protein and urinary albumin.

Test Example 2: Antiproteinuric action in rats with non-insulin-dependent (NIDD) diabetes (Wistar fatty rats) [H. Ikeda et al., Diabetes 30, 1045 (1981)]

On the basis of blood glucose level and urinary protein content, 11-week-old Wistar fatty rats are divided into two groups (vehicle-treated rats and rats treated with 1 mg/kg/day, p.o. of a COMPOUND OF THE INVENTION). Non-diabetic control rats (lean rats) are also used. A COMPOUND OF THE INVENTION is suspended in gum-arabic and the suspension is orally administered once a day for ten days. At the 2nd, 4th, 6th and 8th week of the treatment, 24-hour urine is collected. The urine is centrifuged at 3,000 rpm and a portion of

the supernatant is desalted on a column (Pharmacia PD10). Urinary total protein content and albumin content are determined by Lowry and ELISA methods, respectively.

Cellular proliferation and extracellular matrix accumulation are characteristic features of progressive glomerular diseases in man and a major cause of endstage renal failure.

Test Example 3: Inhibition of mesangial cell proliferation *in vitro*

Interleukin-10 has been shown to stimulate mesangial cell proliferation both *in vitro* and *in vivo* (S. J. Chadban, et al. *Lab. Invest.* 76(5, 1997, 619-627). Proliferation of the 1097 rat mesangial cell line (Y. Kakizaki, et al., *Clin. Exp. Immunol.* 85(1), 1991, 157-63) is assessed by 3H-thymidine uptake. Cells are used between the 30-40th passage. Cells are cultured in RPMI 1640 Medium (Gibco, USA) with heat-inactivated fetal calf serum (FCS), 20 mM HEPES buffer, 100 U/ml penicillin and 100 µg/ml streptomycin in humidified 5% CO₂ atmosphere at 37 °C. Mesangial cells are plated out at low density in 96-well flat-bottomed microtitre plates in RPMI/10% FCS and allowed to adhere overnight. The subconfluent cells are then starved for 3 days in RPMI/0.5% FCS. The media is then replaced by a solution containing 2 µmol/ml of a COMPOUND OF THE INVENTION, prepared freshly by dissolving the COMPOUND OF THE INVENTION in DMSO and diluting this stock solution 1:10 in normal saline, or control, plus or minus cytokines (R&D systems). Cells are cultured for a further 48 hours and pulsed with 3H-thymidine for 6 hours prior to harvesting. IL-10 (20-100ng/ml) is added to selected wells. Duplicates of 6 wells are used in all tests and the tests are repeated 3-5 times. It is observed that IL-10 consistently promotes 1097 proliferation, as compared to control (25-75% increase, $P < 0.01$ - 0.001 vs control). If N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine (CGP 57148B) is used as the COMPOUND OF THE INVENTION, this increase in proliferation is completely inhibited by the addition of the COMPOUND OF THE INVENTION.

Test Example 4: Mesangial proliferative Glomerulonephritis induced in Male Wistar Rats with monoclonal OX-7, anti-rat Thy-1.1 Antibody

Monoclonal OX-7, anti-rat Thy-1.1 antibody is used for the induction of mesangial proliferative glomerulonephritis (D. W. Mason and A. F. Williams, *Biochem. J.* 187(1), 1980, 1-

20), macrophages are detected using ED1, anti-rat CD68 (C. D. Dijkstra et al., Immunology 54(3), 1985, 589-99) myofibroblasts are identified by labelling with 1A4, anti-human α -smooth muscle actin (Sigma Immunochemicals, St. Louis, MO) and M744, anti-BrdU (Dako, Glostrup, Denmark) is used to identify proliferating cells. A polyclonal goat anti-bovine/anti-human type IV collagen antibody (Southern Biotechnology, Birmingham, AL) is used to examine extracellular matrix.

Anti-Thy-1 nephritis is induced in two groups of 8 male Wistar rats (150-170 g) by i.v. injection of 5mg/kg OX-7 IgG (D. J. Nikolic-Paterson et al., J. Am. Soc. Nephrol. 7(7), 1996, 1006-14). Starting one day after OX-7 IgG administration, animals receive daily i.p. injections with either CGP 57148B (50 mg/kg) or vehicle control (10% DMSO in saline) until killed on day 6. 3 hours prior to sacrifice, all rats are given an i.p. injection of 50 mg/kg bromodeoxyuridine (BrdU) in order to label cells in the DNA synthetic (S) phase of the cell cycle. A group of 8 normal rats are also injected with BrdU 3 hours before sacrifice.

Twenty-four hour urine collections and blood samples are taken on days -3 (prior to test) and day 6. Urinary protein concentration is measured by the benzethonium chloride method (Iwata, J. et al., Clin. Chem. 25(7), 1979, 1317-9). Serum and urine creatinine levels are measured using the Jaffé rate reaction (Larsen, K., Clin. Chim. Acta 41, 1972, 209-17).

Tissues are fixed in 4% neutral buffered-formalin and embedded in paraffin. Kidney sections (4 μ m) are stained with periodic-acid Schiff's reagent (PAS). Quantitation of nuclei is performed by examining 50 hilar glomeruli per animal.

Immunostaining is performed as described by Rumble et al., J. Clin. Invest. 99, 1997, 1016-1027. Double immunohistochemical staining is performed in formalin fixed tissue sections using a microwave-based technique to prevent antibody cross-reactivity (G. H. Tesch, et al., Am. J. Pathol. 151(1), 1997, 141-50).

Sections stained with either BrdU or ED1 antibody are scored for ED1+ or BrdU+. Counting is undertaken using a graticule to measure glomerular tuft area and confined to the glomerular tuft thereby omitting cells within the capillary lumen. Fifty glomeruli are scored for each animal and labelled cells expressed as the mean \pm SD per mm². In addition, the number of cells in double-labelled sections are also scored as ED1+BrdU+, ED1+BrdU- and ED1-BrdU+. As podocytes do not proliferate and glomerular endothelial account for <3% of proliferating cells in this disease model proliferating cells are identified as either macrophages ED1+BrdU+ or proliferating mesangial cells as ED1-BrdU+.

The magnitude of immunostaining for type IV collagen is quantified using computer-assisted image analysis as previously described (H. A. Lehr et al., J. Histochem. Cytochem. 45(11), 1997, 1559-65).

Proteinuria is mildly increased in animals that receive OX-7 IgG compared with control rats and is unaffected by CGP 57148B treatment (normal control: 2.1 ± 0.2 mg/24 hours; vehicle-treated Thy-1 nephritis: 13.4 ± 7.2 mg/24 hours, CGP 57148B-treated Thy-1 nephritis: 16.4 ± 7.0 mg/24 hours). In PAS-stained sections mesangial hypercellularity and increased mesangial matrix are noted in glomeruli of untreated rats. These pathological changes are not observed in rats receiving CGP 57148B.

Description of the Figures: Animals with anti-Thy-1 nephritis display moderate glomerular hypercellularity when compared with control animals, as assessed by the nuclear counting and is significantly reduced in rats treated with CGP 57148B (Figure 1). Mesangial cell (BrdU+ED1-) proliferation is increased 5-fold compared with control rats and significantly reduced by treatment with CGP 57148B (Figure 2). Similarly, the number of activated mesangial cells (α -smooth muscle actin positive) is also increased in untreated rats with anti-Thy-1 nephritis and significantly reduced by the administration of CGP 57148B (Figure 3). Marked glomerular matrix accumulation of immunostainable type IV collagen is present in untreated rats with anti-Thy-1 nephritis and significantly reduced by the administration of CGP 57148B (Figure 4).

Test Example 5: Effect of a COMPOUND OF THE INVENTION on experimental diabetic nephropathy in Sprague-Dawley rats weighing 200 to 250 g

Diabetes is induced in the above rats by injection of streptozotocin (STZ, 55 mg/kg). All animals which develop diabetes within 7 days (random glucose > 15 mmol/l) are used for the following test. All diabetic rats receive insulin (human ultralente) 2 units/day to maintain body weight and to avoid ketonuria without euglycaemia leading to glucose levels of 20-25 mM. Control rats are sham injected with buffer alone. A COMPOUND OF THE INVENTION, e.g. CGP 57148B, is administered by gavage at a dose of 20 mg/kg/day. STZ-diabetic rats are randomized to receive the COMPOUND OF THE INVENTION or vehicle. Study groups comprising 16 rats each are as follows: (I) control rats, no drug, (II) control rat, the COMPOUND OF THE INVENTION, (III) STZ-diabetic rat, no drug, (IV) STZ-diabetic rat, the

COMPOUND OF THE INVENTION. In weeks 0, 1, 4, 8, 12, 24 and 32 the body weight, blood pressure, glucose, HbA_{1c}, water intake and food intake are determined. Histological assessment of the glomeruli and tubulointerstitium are carried out at the end of the study. Glomerular structure is assessed by quantitative electron microscopy histomorphometry. The removed kidneys of the rats are analysed for GBM thickness and fractional mesangial volume.

By the obtained results, e.g. by the amelioration of the pathological findings of mesangial proliferative glomerulonephritis, in particular the amelioration of mesangial hypercellularity and matrix accumulation, it is shown that the COMPOUNDS OF THE INVENTION can be used for the prevention or preferably treatment especially of diabetic nephropathy, but also of glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

Preference is given to COMPOUNDS OF THE INVENTION of formula I wherein one or two of the radicals R₄, R₅, R₆, R₇ and R₈ are each nitro or a radical of formula II wherein

R₉ is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R₁₀ is an aliphatic radical having at least 5 carbon atoms or an aromatic, aromatic--aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical,

and the remaining radicals R₄, R₅, R₆, R₇ and R₈ are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino or free or esterified carboxy,

and the remaining substituents are as defined above.

Preference is given especially to COMPOUNDS OF THE INVENTION of formula I wherein

R₁ is pyridyl or N-oxido-pyridyl each of which is bonded at a carbon atom,

R₂ and R₃ are each hydrogen,

R₄ is hydrogen or lower alkyl,

R₅ is hydrogen, lower alkyl or trifluoromethyl,

R₆ is hydrogen,

R₇ is nitro, fluoro-substituted lower alkoxy or a radical of formula II wherein

R₉ is hydrogen,

X is oxo,

n is 0 and

R₁₀ is pyridyl bonded at a carbon atom, phenyl that is unsubstituted or substituted by halogen, cyano, lower alkoxy, carboxy, lower alkyl or by 4-methyl-piperazinyl-methyl, or C₅-C₇alkyl, thienyl, 2-naphthyl or cyclohexyl, and

R₈ is hydrogen.

Special preference is given to COMPOUNDS OF THE INVENTION of formula I wherein at least one of the radicals R₄ and R₈ is lower alkyl, and the remaining substituents are as defined above.

Preference is given above all to COMPOUNDS OF THE INVENTION of formula I wherein R₁ is pyridyl bonded at a carbon atom, R₂, R₃, R₅, R₆ and R₈ are each hydrogen, R₄ is lower alkyl, R₇ a radical of formula II wherein R₉ is hydrogen, X is oxo, n is 0 and R₁₀ is 4-methyl-piperazinyl-methyl.

Preference is given above all especially to the COMPOUND OF THE INVENTION of formula I which is CGP 57148B {N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine}.

Very preferably a COMPOUND OF THE INVENTION is used in the form of its monomesylate salt.

The COMPOUNDS OF THE INVENTION of formula I are generically and specifically disclosed in the patent applications EP 0 564 409 A1 and WO 99/03854, in particular in the compound claims and the final products of the working examples, the subject-matter of the final products, the pharmaceutical preparations and the claims are hereby incorporated into the present application by reference to these publications. Comprised are likewise the corresponding stereoisomers as well as the corresponding polymorphs, e.g. crystal modifications, which are disclosed therein.

In EP 0 564 409 A1 the COMPOUNDS OF THE INVENTION of formula I are described to be useful for the therapy of cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis and atherosclerosis. In accordance with the present invention it has now been found that COMPOUNDS OF THE INVENTION surprisingly have a beneficial effect on diabetic nephropathy, glomerulonephritis, chronic pyelonephritis and IgA nephropathy.

In a preferred embodiment of the invention COMPOUNDS OF THE INVENTION are used for the manufacture of a medicament for treating diabetic nephropathy, glomerulonephritis, chronic pyelonephritis or IgA nephropathy, which use is accompanied by the reduction of side effects compared to other medicaments for treating diabetic nephropathy, glomerulonephritis, chronic pyelonephritis or IgA nephropathy which are known in the art.

Preferably, the COMPOUNDS OF THE INVENTION are used for the manufacture of a medicament for the treatment of diabetic nephropathy.

In accordance with the particular findings of the invention, the present invention also provides a method of treatment of warm-blooded animals, including humans, in which an therapeutically effective dose of a COMPOUND OF THE INVENTION is administered to such a warm-blooded animal suffering from glomerulonephritis, chronic pyelonephritis, IgA nephropathy or, preferably, from diabetic nephropathy.

In one preferred embodiment of the invention, the administration of the medicament comprising a COMPOUND OF THE INVENTION effects a reduction of glomerular hypercellularity, of mesangial cell proliferation or of the number of activated mesangial cells, compared to the amount of glomerular hypercellularity, mesangial cell proliferation or the num-

ber of activated mesangial cells in a warm blooded animals in one of the test systems described herein or, preferably, in humans suffering from a progressive glomerular disease.

In another preferred embodiment of the invention, the administration of the medicament comprising a COMPOUND OF THE INVENTION effects a reduction of glomerular matrix accumulation of immunostainable type IV collagen compared to the amount of glomerular matrix accumulation in warm blooded animals with an increased glomerular matrix accumulation of immunostainable type IV collagen, in one of the test systems described herein, for example rats with anti-Thy-1 nephritis, or, preferably, in humans suffering from a progressive glomerular disease.

The term "method of treatment" used herein relates especially also to a method of prevention of the diseases mentioned herein, i.e. the prophylactic administration of a pharmaceutical composition comprising a COMPOUND OF THE INVENTION to healthy patients to prevent the outbreak of the diseases mentioned herein, especially diabetic nephropathy.

The present invention relates also to a pharmaceutical composition for the treatment of glomerulonephritis, chronic pyelonephritis, IgA nephropathy or, preferably, of diabetic nephropathy.

Pharmaceutical compositions for the treatment of diabetic nephropathy, glomerulonephritis, chronic pyelonephritis or IgA nephropathy are comprising an effective amount of the COMPOUNDS OF THE INVENTION together with pharmaceutically acceptable carriers that are suitable for topical, enteral, for example oral or rectal, or parenteral administration, and may be inorganic or organic, solid or liquid. For oral administration there are used especially tablets or gelatin capsules comprising the COMPOUNDS OF THE INVENTION together with diluents, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycerol, and/or lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Tablets may also comprise binders, for example magnesium aluminium silicate, starches, such as corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorbents, dyes, flavourings and sweeteners. The COMPOUNDS OF THE INVENTION can also be used in the

form of parenterally administrable compositions or in the form of infusion solutions. Such solutions are preferably isotonic aqueous solutions or suspensions, which, for example in the case of lyophilised compositions that comprise at least one COMPOUND OF THE INVENTION alone or together with a carrier, for example mannitol, can be prepared before use. The pharmaceutical compositions may be sterilised and/or may comprise excipients, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical compositions which, if desired, may comprise further pharmacologically active substances, such as antibiotics or antidiabetically active compounds, are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes, and comprise approximately from 1 % to 100 %, especially from approximately 1 % to approximately 20 %, active ingredient(s).

The COMPOUNDS OF THE INVENTION can, for example, be formulated as disclosed in Examples 4 and 6 of WO 99/03854.


The dosage range of the COMPOUNDS OF THE INVENTION to be employed depends upon factors known to the person skilled in the art including species of the warm-blooded animal, body weight and age, the mode of administration, the particular substance to be employed and the disease to be treated. Unless stated otherwise herein, the COMPOUNDS OF THE INVENTION are preferably administered from one to four times per day. Furthermore, the COMPOUNDS OF THE INVENTION, especially N-(5-[4-(4-methylpiperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine (CGP 57148B), are preferably administered to the warm-blooded animal in a dosage in the range of about 1 to 1000mg, more preferably 50 to 500mg and most preferably 25 to 250 mg/day, especially when the warm-blooded animal is a human of about 70 kg body weight.

WHAT IS CLAIMED IS:

1. Use of a PDGF receptor tyrosine kinase inhibitor for the manufacture of a medicament for treating diabetic nephropathy.

2. Use of a PDGF receptor tyrosine kinase inhibitor according to claim 1 wherein the PDGF receptor tyrosine kinase inhibitor is a N-phenyl-2-pyrimidine-amine derivative of the formula

I



wherein

R₁ is 4-pyrazinyl; 1-methyl-1H-pyrrolyl; amino- or amino-lower alkyl-substituted phenyl, wherein the amino group in each case is free, alkylated or acylated; 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom; or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen;

R₂ and R₃ are each independently of the other hydrogen or lower alkyl;

one or two of the radicals R₄, R₅, R₆, R₇ and R₈ are each nitro, fluoro-substituted lower alkoxy or a radical of formula II



wherein

R₉ is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R₁₀ is an aliphatic radical having at least 5 carbon atoms, or an aromatic, aromatic--aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical,

and the remaining radicals R₄, R₅, R₆, R₇ and R₈ are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino or free or esterified carboxy,

or a salt of such a compound having at least one salt-forming group,
for the manufacture of a medicament for treating diabetic nephropathy.

3. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to claim 2,
wherein

one or two of the radicals R₄, R₅, R₆, R₇ and R₈ are each nitro or a radical of formula II
wherein

R₉ is hydrogen or lower alkyl,

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino or O-lower alkyl-hydroximino,

Y is oxygen or the group NH,

n is 0 or 1 and

R₁₀ is an aliphatic radical having at least 5 carbon atoms or an aromatic, aromatic--aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical,

and the remaining radicals R₄, R₅, R₆, R₇ and R₈ are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino or free or esterified carboxy,

and the remaining substituents are as defined in claim 1,

or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

4. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to any one of claims 2 or 3, wherein

R₁ is pyridyl or N-oxido-pyridyl each of which is bonded at a carbon atom,

R₂ and R₃ are each hydrogen,

R₄ is hydrogen or lower alkyl,

R₅ is hydrogen, lower alkyl or trifluoromethyl,

R₆ is hydrogen,

R₇ is nitro, fluoro-substituted lower alkoxy or a radical of formula II wherein

R₉ is hydrogen,

X is oxo,

n is 0 and

R₁₀ is pyridyl bonded at a carbon atom, phenyl that is unsubstituted or substituted by halogen, cyano, lower alkoxy, carboxy, lower alkyl or by 4-methyl-piperazinyl-methyl, or C₅-C₇alkyl, thienyl, 2-naphthyl or cyclohexyl, and

R₈ is hydrogen,

or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

5. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to any one of claims 2 to 4, wherein

at least one of the radicals R₄ and R₈ is lower alkyl, and the remaining substituents are as defined in the respective generic claim,

or a pharmaceutically acceptable salt of such a compound having at least one salt-forming group.

6. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to one of claims 2 to 5, wherein

R₁ is pyridyl bonded at a carbon atom,

R₂, R₃, R₅, R₆ and R₈ are each hydrogen,

R₄ is lower alkyl,

R₇ a radical of formula II wherein

R₉ is hydrogen,


X is oxo,

n is 0 and

R₁₀ is 4-methyl-piperazinyl-methyl,

or a pharmaceutically acceptable salt thereof.

7. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to claim 2, which inhibitor is N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof.
8. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to any one of claims 2 to 7, wherein the compound is used in the form of its monomesylate salt.
9. Method of treatment of a warm-blooded animal having diabetic nephropathy comprising administering to the animal a PDGF receptor tyrosine kinase inhibitor as defined in any one of claims 1 to 8 in a quantity which is therapeutically effective against diabetic nephropathy in which the PDGF receptor tyrosine kinase inhibitor can also be present in the form of a pharmaceutically acceptable salt.
10. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I,



wherein

R₁ is pyridyl bonded at a carbon atom,

R₂, R₃, R₅, R₆ and R₈ are each hydrogen,

R₄ is lower alkyl,

R₇ a radical of formula II wherein

R₉ is hydrogen,

X is oxo,

n is 0 and

R₁₀ is 4-methyl-piperazinyl-methyl,

or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

11. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to claim 10, which inhibitor is

N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine,

or a pharmaceutically acceptable salt thereof.


12. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to claim 10 or 11, wherein the PDGF receptor tyrosine kinase inhibitor is used in the form of its monomesylate salt.

13. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to any one of claims 10, 11 or 12, wherein the administration of the medicament effects a reduction of glomerular hypercellularity, of mesangial cell proliferation or of the number of activated mesangial cells in warm blooded animals suffering from a progressive glomerular disease.

14. Use of a PDGF receptor tyrosine kinase inhibitor of the formula I according to any one of claims 10, 11 or 12, wherein the administration of the medicament effects a reduction of glomerular matrix accumulation of immunostainable type IV collagen in warm blooded animals suffering from a progressive glomerular disease.

Abstract

The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula I,




in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula I, wherein R₁ is pyridyl bonded at a carbon atom, R₂, R₃, R₅, R₆ and R₈ are each hydrogen, R₄ is lower alkyl, R₇ a radical of formula II



wherein R₉ is hydrogen, X is oxo, n is 0 and R₁₀ is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

1/4

Figure 1




Figure 2





Figure 3

4/4

Figure 4

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64200 A3

- (51) International Patent Classification⁷: **A61K 31/505**, 31/506, 31/00, A61P 13/12
- (21) International Application Number: **PCT/EP01/02340**
- (22) International Filing Date: **1 March 2001 (01.03.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
00810181.8 **3 March 2000 (03.03.2000)** **EP**
- (71) Applicants (for all designated States except US): **NOVARTIS AG [CH/CH]**; Lichtstrasse 35, CH-4056 Basel (CH). **THE UNIVERSITY OF MELBOURNE [AU/AU]**; Parkville, VIC 3052 (AU). **SOUTHERN HEALTH [AU/AU]**; Monash Medical Center, 246 Clayton Road, Clayton, VIC 3168 (AU).
- (72) Inventors: **ATKINS, Robert, Charles [AU/AU]**; 7 Wentworth Avenue, Canterbury, VIC 3126 (AU). **CHADBAN, Steven, James [AU/AU]**; 73 Ardoyne Street, Blackrock, VIC 3193 (AU). **COOPER, Mark, Emmanuel [AU/AU]**; 50 Molesworth Street, Kew, VIC 3101 (AU). **GILBERT, Richard, Ernest [AU/AU]**; 16 Mary Street, West St. Kilda, VIC 3182 (AU). **HILL, Prudence, Ann [AU/AU]**; 7 Wentworth Avenue, Canterbury, VIC 3126 (AU). **KELLY, Darren, James [AU/AU]**; 1 Commerford Place, Chirnside Village, VIC 3116 (AU). **NIKOLIC-PAETERSON, David, John [GB/AU]**; 170 Mt. Grantview Road, Pearcedale, VIC 3912 (AU).
- (74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
17 January 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY**



(57) Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R_1 is pyridyl bonded at a carbon atom, R_2 , R_3 , R_5 , R_6 and R_8 are each hydrogen, R_4 is lower alkyl, R_7 a radical of formula (II): $-N(R_9)-C(=X)-(Y)_n-R_{10}$, wherein R_9 is hydrogen, X is oxo, n is 0 and R_{10} is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture

of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/EP 01/02340

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/505 A61K31/506 A61K31/00 A61P13/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>EP 0 564 409 A (CIBA GEIGY AG) 6 October 1993 (1993-10-06) cited in the application abstract page 2, line 4 -page 4, line 1 page 5, line 1 - line 49 page 6, line 26 - line 37 page 13, line 33 - line 40 example 21 claims 1-10</p> <p style="text-align: center;">--- -/--</p>	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

19 October 2001

Date of mailing of the international search report

16/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Cielen, E

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/EP 01/02340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 03854 A (NOVARTIS ERFINDUNGEN VERWALTUN ;NOVARTIS AG (CH); BUEGER HANS MIC) 28 January 1999 (1999-01-28) cited in the application abstract page 1, paragraph 1 page 3, paragraph 4 - paragraph 6 page 10, paragraph 1 page 11, paragraph 1 page 16, paragraph 3 -page 17, paragraph 1 claims	1-14
Y	WO 00 09098 A (NOVARTIS ERFINDUNGEN VERWALTUN ;NOVARTIS AG (CH); WOOD JEANETTE MA) 24 February 2000 (2000-02-24) page 11, line 10 -page 12, last paragraph	1-14
X	WO 96 33179 A (SUGEN INC ;TANG PENG CHO (US)) 24 October 1996 (1996-10-24)	1,9
Y	abstract page 5, line 12 -page 6, line 10 page 8, line 11 - line 22 page 11, line 28 -page 12, line 1 page 14, line 6 -page 15, line 7 page 30, line 6 -page 31, line 13 claims 14,18	1-13
X	EP 0 826 686 A (TAKEDA CHEMICAL INDUSTRIES LTD) 4 March 1998 (1998-03-04)	1,9
Y	abstract page 2, line 1 - line 7 page 2, line 46 -page 3, line 26 page 36, line 27 - line 35 page 37, line 23 - line 28 page 59, line 39 -page 60, line 20 claims 1-4,38-47	1-13
Y	BARAN, DANA ET AL: "The new tyrosine kinase inhibitor CGP 53716 specifically inhibits PDGF-driven murine mesangial cell (MC) proliferation." JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (SEPT., 1997) VOL. 9, NO. PROGRAM AND ABSTR. ISSUE, PP. 433A. MEETING INFO.: 30TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY SAN ANTONIO, TEXAS, USA NOVEMBER 2-5, 1997 AMERICAN SOCIETY OF NEPHR, XPO02143111 the whole document	10-13
	--- -/--	

INTERNATIONAL SEARCH REPORT

Inte. .onal Application No
PCT/EP 01/02340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BIRD EILEEN ET AL: "Effects of a platelet-derived growth factor (PDGF) receptor kinase inhibitor, RPR-101511a, in acute glomerulonephritis in rats." JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. PROGRAM AND ABSTR. ISSUE, 1999, page 568A XP001032450 32nd Annual Meeting of the American Society of Nephrology; Miami Beach, Florida, USA; November 1-8, 1999 ISSN: 1046-6673 the whole document ---	10,13,14
Y	WO 96 13259 A (COR THERAPEUTICS INC) 9 May 1996 (1996-05-09) abstract page 2, paragraph 3 -page 3, paragraph 2 claims 1,11,14,22 ---	10-12
Y	WOO K T: "Recent concepts in the pathogenesis and therapy of IgA nephritis." ANNALS ACADEMY OF MEDICINE SINGAPORE, vol. 25, no. 2, 1996, pages 265-269, XP001032441 ISSN: 0304-4602 abstract page 267, column 1, paragraph 6 ---	10-12
A	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SUGIMOTO, YUKIO ET AL: "Preparation of N-(hetero)aryl-p-aminophenol derivatives for elimination of active oxygen species" retrieved from STN Database accession no. 116:41485 XP002143112 abstract & JP 03 184914 A (OTSUKA PHARMACEUTICAL FACTORY, INC., JAPAN) 12 August 1991 (1991-08-12) --- -/--	1-10

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/02340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>GILBERT RICHARD E ET AL: "PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis." KIDNEY INTERNATIONAL, vol. 59, no. 4, April 2001 (2001-04), pages 1324-1332, XP001032815 ISSN: 0085-2538 abstract page 1324, column 2, paragraph 3 -page 1325, column 1, paragraph 1 figures 2-4 page 1328, column 1, paragraph 4 -page 1329, column 1, paragraph 2 page 1331, column 1, paragraph 1 -column 2, paragraph 2</p>	<p>10,11, 13,14</p>
A	<p>WO 99 58128 A (EYERS PATRICK ALEXANDER ;MEDICAL RES COUNCIL (GB); COHEN PHILIP (G) 18 November 1999 (1999-11-18) page 9, line 20 - line 24 page 13, line 1 - line 10 page 28, line 16 -page 29, line 28 page 32, line 11 - line 20 claims 1,10,18,21,22</p>	<p>1,9,10, 14</p>

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Present claims 1 and 9 relate to a compound which actually is not well-defined. The use of the definition "a PDGF receptor tyrosine kinase inhibitor" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the compounds which have been defined in claims 2-8 and 10-14.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/02340

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0564409	A	06-10-1993	AT 188964 T	15-02-2000
			AU 3569493 A	07-10-1993
			BR 1100739 A3	06-06-2000
			CA 2093203 A1	04-10-1993
			CN 1077713 A ,B	27-10-1993
			CZ 9300560 A3	16-02-1994
			DE 59309931 D1	24-02-2000
			DK 564409 T3	19-06-2000
			EP 0564409 A1	06-10-1993
			ES 2142857 T3	01-05-2000
			FI 931458 A	04-10-1993
			GR 3032927 T3	31-07-2000
			HU 64050 A2	29-11-1993
			IL 105264 A	11-04-1999
			JP 2706682 B2	28-01-1998
			JP 6087834 A	29-03-1994
			KR 261366 B1	01-08-2000
			MX 9301929 A1	29-07-1994
			NO 302473 B1	09-03-1998
			NZ 247299 A	26-07-1995
			PT 564409 T	30-06-2000
			RU 2125992 C1	10-02-1999
			SG 43859 A1	14-11-1997
			SK 28093 A3	06-04-1994
			US 5521184 A	28-05-1996
			ZA 9302397 A	04-10-1993
WO 9903854	A	28-01-1999	AU 8975998 A	10-02-1999
			BR 9810920 A	15-08-2000
			CN 1264375 T	23-08-2000
			WO 9903854 A1	28-01-1999
			EP 0998473 A1	10-05-2000
			HU 0003230 A2	28-06-2001
			JP 2001510192 T	31-07-2001
			NO 20000227 A	17-01-2000
			PL 338129 A1	25-09-2000
			SK 432000 A3	12-06-2000
			TR 200000060 T2	21-09-2000
			ZA 9806362 A	22-01-1999
WO 0009098	A	24-02-2000	AU 5733099 A	06-03-2000
			WO 0009098 A2	24-02-2000
			EP 1105136 A2	13-06-2001
WO 9633179	A	24-10-1996	US 5721277 A	24-02-1998
			AU 5559396 A	07-11-1996
			WO 9633179 A1	24-10-1996
			US 5760066 A	02-06-1998
			US 5914343 A	22-06-1999
EP 0826686	A	04-03-1998	CA 2214393 A1	02-03-1998
			CN 1176785 A	25-03-1998
			EP 0826686 A2	04-03-1998
			JP 10120568 A	12-05-1998
			JP 10182644 A	07-07-1998
			US 6251905 B1	26-06-2001
			US 5958942 A	28-09-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. onal Application No

PCT/EP 01/02340

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9613259	A	09-05-1996	US 5795910 A	18-08-1998
			AU 706621 B2	17-06-1999
			AU 4278996 A	23-05-1996
			CA 2203757 A1	09-05-1996
			CN 1165481 A	19-11-1997
			EP 0788356 A2	13-08-1997
			JP 10508024 T	04-08-1998
			WO 9613259 A2	09-05-1996
			US 5728726 A	17-03-1998
			US 5674892 A	07-10-1997
JP 3184914	A	12-08-1991	JP 2602735 B2	23-04-1997
WO 9958128	A	18-11-1999	AU 3834899 A	29-11-1999
			EP 1076560 A1	21-02-2001
			WO 9958128 A1	18-11-1999